Mary Miller - 26 Sep 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
26 Sep 2023
Net transactions value
$0
Form type
4
Filing time
28 Sep 2023, 19:17:49 UTC
Previous filing
24 Mar 2022
Next filing
19 Oct 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Award $0 +3,858 +9.5% $0.000000 44,287 26 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +11,576 $0.000000 11,576 26 Sep 2023 Common Stock 11,576 $8.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) shall vest on October 1, 2024, and the remaining RSUs shall vest in three substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2 Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2024, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.